ストックスクリーナーアプリを入手
75.64
0.27%
0.20
前日終値:
$75.44
開ける：
$75.83
24時間の取引高:
886.80K
Relative Volume:
0.59
時価総額：
$6.07B
収益：
$900.66M
当期純損益:
$-453.20M
株価収益率:
-12.73
EPS:
-5.94
ネットキャッシュフロー:
$-274.19M
1週間 パフォーマンス:
-2.09%
1か月 パフォーマンス:
+0.92%
6か月 パフォーマンス:
+48.37%
1年 パフォーマンス:
+59.71%
1日の値動き範囲:
$74.50
$76.16
1週間の範囲:
$73.09
$78.77
52週間の値動き範囲:
$35.95
$87.50
Ptc Therapeutics Inc Stock (PTCT) Company Profile
名前
Ptc Therapeutics Inc
セクター
電話
(908) 222-7000
住所
500 WARREN CORPORATE CENTER DRIVE, WARREN, NJ
PTCT を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
PTCT
Ptc Therapeutics Inc
|
75.64 | 6.06B | 900.66M | -453.20M | -274.19M | -5.94 |
|
VRTX
Vertex Pharmaceuticals Inc
|
452.04 | 113.14B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
741.29 | 78.49B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
877.94 | 54.76B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
397.55 | 54.51B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
INSM
Insmed Inc
|
197.01 | 41.64B | 447.02M | -1.18B | -906.14M | -6.1812 |
Ptc Therapeutics Inc Stock (PTCT) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-12-01 | ダウングレード | RBC Capital Mkts | Outperform → Sector Perform |
| 2025-10-20 | 開始されました | Wells Fargo | Overweight |
| 2025-06-17 | 開始されました | Truist | Buy |
| 2025-05-09 | アップグレード | BofA Securities | Neutral → Buy |
| 2025-05-07 | アップグレード | Citigroup | Sell → Neutral |
| 2025-03-11 | アップグレード | BofA Securities | Underperform → Neutral |
| 2025-03-07 | 開始されました | Scotiabank | Sector Perform |
| 2024-12-13 | アップグレード | Morgan Stanley | Equal-Weight → Overweight |
| 2024-12-03 | アップグレード | RBC Capital Mkts | Sector Perform → Outperform |
| 2024-10-10 | 再開されました | Raymond James | Mkt Perform |
| 2024-09-04 | 開始されました | Robert W. Baird | Outperform |
| 2024-08-26 | 再開されました | UBS | Buy |
| 2024-05-20 | アップグレード | Raymond James | Underperform → Mkt Perform |
| 2023-12-19 | ダウングレード | Morgan Stanley | Equal-Weight → Underweight |
| 2023-12-08 | 開始されました | Wells Fargo | Overweight |
| 2023-10-30 | アップグレード | Oppenheimer | Perform → Outperform |
| 2023-10-27 | ダウングレード | Citigroup | Neutral → Sell |
| 2023-10-06 | ダウングレード | Truist | Buy → Hold |
| 2023-09-18 | ダウングレード | Citigroup | Buy → Neutral |
| 2023-09-15 | ダウングレード | Raymond James | Outperform → Underperform |
| 2023-03-17 | 開始されました | SVB Securities | Market Perform |
| 2022-12-14 | 開始されました | Goldman | Sell |
| 2022-09-12 | 開始されました | Jefferies | Buy |
| 2022-09-09 | 開始されました | Morgan Stanley | Equal-Weight |
| 2022-09-01 | 開始されました | Citigroup | Buy |
| 2022-04-04 | 再開されました | Cantor Fitzgerald | Overweight |
| 2021-10-18 | ダウングレード | BofA Securities | Neutral → Underperform |
| 2021-04-26 | 再開されました | Credit Suisse | Neutral |
| 2021-03-29 | アップグレード | RBC Capital Mkts | Underperform → Sector Perform |
| 2021-02-12 | ダウングレード | BofA Securities | Buy → Neutral |
| 2021-01-05 | アップグレード | Citigroup | Neutral → Buy |
| 2020-11-30 | ダウングレード | RBC Capital Mkts | Sector Perform → Underperform |
| 2020-10-30 | ダウングレード | Citigroup | Buy → Neutral |
| 2020-10-28 | 開始されました | UBS | Neutral |
| 2020-10-07 | アップグレード | JP Morgan | Neutral → Overweight |
| 2020-08-25 | 開始されました | Raymond James | Outperform |
| 2020-04-09 | アップグレード | Citigroup | Neutral → Buy |
| 2020-02-20 | ダウングレード | Citigroup | Buy → Neutral |
| 2020-02-20 | ダウングレード | RBC Capital Mkts | Outperform → Sector Perform |
| 2019-11-12 | 開始されました | SunTrust | Buy |
| 2019-05-13 | アップグレード | BofA/Merrill | Neutral → Buy |
| 2019-04-11 | 開始されました | Bernstein | Outperform |
| 2018-10-03 | アップグレード | BofA/Merrill | Underperform → Neutral |
| 2018-10-01 | 開始されました | Cantor Fitzgerald | Overweight |
| 2018-07-19 | 開始されました | Credit Suisse | Outperform |
| 2018-06-18 | アップグレード | RBC Capital Mkts | Sector Perform → Outperform |
| 2018-04-04 | ダウングレード | Barclays | Equal Weight → Underweight |
| 2018-01-29 | 再開されました | RBC Capital Mkts | Sector Perform |
| 2017-11-16 | アップグレード | JP Morgan | Underweight → Neutral |
| 2017-10-26 | ダウングレード | BofA/Merrill | Neutral → Underperform |
| 2017-10-09 | ダウングレード | JP Morgan | Neutral → Underweight |
すべてを表示
Ptc Therapeutics Inc (PTCT) 最新ニュース
Armistice Capital LLC Has $231.28 Million Position in PTC Therapeutics, Inc. $PTCT - MarketBeat
PTC Therapeutics Announces Health Canada Approval of Sephience™ (sepiapterin) for the Treatment of Children and Adults Living with Phenylketonuria (PKU) - BioSpace
PTC Therapeutics Announces Health Canada Approval of Sephience™ (sepiapterin) for the Treatment of Children and Adults Living with Phenylketonuria (PKU) – Company AnnouncementFT.com - Financial Times
Marshall Wace LLP Reduces Stake in PTC Therapeutics, Inc. $PTCT - MarketBeat
PTC Therapeutics, Inc. $PTCT Stock Position Raised by Hood River Capital Management LLC - MarketBeat
Emma Reeve Sells 733 Shares of PTC Therapeutics (NASDAQ:PTCT) Stock - MarketBeat
PTC Therapeutics (NASDAQ:PTCT) Downgraded to Hold Rating by Wall Street Zen - MarketBeat
Can PTC Therapeutics Inc. (BH3) stock sustain breakout momentumShare Buyback & Weekly Watchlist for Consistent Profits - Newser
Russell Investments Group Ltd. Buys 118,105 Shares of PTC Therapeutics, Inc. $PTCT - MarketBeat
How higher bond yields impact PTC Therapeutics Inc. (BH3) stock2025 Price Action Summary & Step-by-Step Trade Execution Guides - Newser
Insider Selling: PTC Therapeutics (NASDAQ:PTCT) CEO Sells $271,051.96 in Stock - MarketBeat
Rare-Disease Biotech PTC Is Surging — And One Fund Just Raised Its Bet. Should You? - AOL.com
Why PTC Therapeutics Inc. stock could rally in 2025Inflation Watch & Target Return Focused Picks - Newser
Will PTC Therapeutics Inc. (BH3) stock outperform global peers2025 Analyst Calls & Entry Point Strategy Guides - Newser
PTC Therapeutics (NASDAQ:PTCT) Shares Down 5.6%Time to Sell? - MarketBeat
Transcript : PTC Therapeutics, Inc. Presents at Citi Annual Global Healthcare Conference 2025, Dec-04-2025 10 - marketscreener.com
Panagora Asset Management Inc. Lowers Stock Holdings in PTC Therapeutics, Inc. $PTCT - MarketBeat
PTC Therapeutics (PTCT): Revisiting Valuation After Strong Multi‑Year Share Price Gains - Yahoo Finance
PTC Therapeutics (PTCT) Gets a Sell from Goldman Sachs - The Globe and Mail
PTC Therapeutics Swings to a Profit on $211 Million in Revenue — Is This Why a Major Fund Just Invested $32 Million? - Nasdaq
PTC Therapeutics downgraded at RBC as Sephience sales priced in - MSN
PTC Therapeutics Investors Focus on Sephience Uptake, Huntington's Updates, RBC Says - marketscreener.com
Prudential Financial Inc. Has $4.12 Million Position in PTC Therapeutics, Inc. $PTCT - MarketBeat
PTC Therapeutics stock price target raised to $55 from $50 at Goldman Sachs - Investing.com UK
Legal & General Group Plc Grows Stock Position in PTC Therapeutics, Inc. $PTCT - MarketBeat
Transcript : PTC Therapeutics, Inc. Presents at Jefferies London Healthcare Conference 2025, Nov-18-2025 08 - marketscreener.com
Can PTC Therapeutics Inc. (BH3) stock retain market dominance2025 Support & Resistance & Low Risk High Reward Trade Ideas - Newser
How PTC Therapeutics Inc. (BH3) stock moves on employment dataQuarterly Earnings Report & Long-Term Capital Growth Strategies - Newser
Is PTC Therapeutics Inc. stock a buy for dividend growth2025 Trading Recap & Reliable Volume Spike Trade Alerts - Newser
Why PTC Therapeutics Inc stock could rally in 2025Weekly Earnings Recap & Fast Gain Swing Trade Alerts - BỘ NỘI VỤ
Will PTC Therapeutics Inc. (BH3) stock deliver stable dividendsPortfolio Value Summary & Accurate Intraday Trade Tips - Newser
This Fund Sold $30 Million in PTC Therapeutics Shares Amid a 93% Rally: Here’s Why - AOL.com
Cadrenal Therapeutics appoints PTC Therapeutics CMO to board By Investing.com - Investing.com Australia
PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - PR Newswire
PTC Therapeutics Shares Drop After RBC Downgrade - marketscreener.com
PTC Therapeutics downgraded at RBC as Sephience sales priced in (PTCT:NASDAQ) - Seeking Alpha
Cadrenal Therapeutics, Inc. Appoints Dr. Lee Scott Golden to Board of Directors - Quiver Quantitative
Cadrenal Therapeutics Appoints Dr. Lee Golden to Board of Directors - The Manila Times
Cadrenal Therapeutics appoints PTC Therapeutics CMO to board - Investing.com
PTC Therapeutics stock downgraded by RBC Capital as shares near fair value - Investing.com Canada
RBC Downgrades PTC Therapeutics to Sector Perform From Outperform, Lifts Price Target to $91 From $82 - marketscreener.com
(PTCT) Price Dynamics and Execution-Aware Positioning - news.stocktradersdaily.com
Elo Mutual Pension Insurance Co Makes New $689,000 Investment in PTC Therapeutics, Inc. $PTCT - MarketBeat
How The Sephience Launch Is Reshaping The Story For PTC Therapeutics’s Valuation - Yahoo Finance
A PTC Therapeutics (PTCT) Insider Sold 10,000 Shares for $795,000 - The Globe and Mail
Advantage Alpha Capital Partners LP Invests $204,000 in PTC Therapeutics, Inc. $PTCT - MarketBeat
PTC Therapeutics (PTCT) Stock on November 28, 2025: S&P SmallCap 600 Debut, Insider Selling and a 90% YTD Rally - ts2.tech
PTC Therapeutics, Inc.(NasdaqGS: PTCT) added to S&P 600 Health Care - marketscreener.com
PTC Therapeutics, Inc.(NasdaqGS: PTCT) added to S&P Composite 1500 - marketscreener.com
PTC Therapeutics, Inc.(NasdaqGS: PTCT) added to S&P 600 - marketscreener.com
Ptc Therapeutics Inc (PTCT) 財務データ
収益
当期純利益
現金流量
EPS
Ptc Therapeutics Inc (PTCT) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| Reeve Emma | Director |
Dec 03 '25 |
Sale |
78.62 |
733 |
57,628 |
6,666 |
| Klein Matthew B. | CHIEF EXECUTIVE OFFICER |
Dec 02 '25 |
Sale |
79.07 |
3,428 |
271,052 |
349,964 |
1.08%
0.91%
大文字化:
|
ボリューム (24 時間):